On June 25, 2026, the Supreme Court handed the maker of Roundup weed killer a major win, and made it harder for ordinary people to sue companies that fail to warn them about a product’s dangers. By a 7-2 vote in Monsanto v. Durnell, the Court threw out a $1.25 million verdict won by a man who developed cancer after spraying Roundup for two decades, ruling that a federal pesticide law blocks his claim under state law. The decision also cleared the way for a $7.25 billion settlement meant to resolve tens of thousands of similar Roundup lawsuits.
For a firm that represents people harmed by dangerous products, this is a hard result. But it is narrower than the headlines suggest, and understanding why matters, especially if you have been hurt by a medication or a medical device and not just a pesticide.
At the heart of the case is a legal idea called “preemption.” When Congress passes a federal law, that law can override, or “preempt,” conflicting state laws, including a person’s right to sue under state rules. The question here was whether the federal pesticide law preempts a lawsuit claiming that Roundup’s label should have carried a cancer warning.
What the Court Decided
For a free legal consultation, call,
(888) 585-2188
The federal law, known as FIFRA, tells states they cannot require pesticide warning labels that differ from what the federal government requires. The Environmental Protection Agency (EPA), which approves pesticide labels, has studied Roundup’s main ingredient, glyphosate, many times and concluded it is not likely to cause cancer. So the EPA never required a cancer warning on the label.
Here is the pivotal move. The Court held that once the EPA approves a label, the company is legally locked into using that exact label until the agency says otherwise. A jury verdict demanding a cancer warning the EPA never required, the Court reasoned, is a state demand “different from” the federal one, and so it is blocked. To get there, the majority leaned almost entirely on an older case about medical devices, Riegel v. Medtronic, in which the Court had said that FDA approval of a device creates federal “requirements” that block state lawsuits. If FDA approval of a device works that way, the majority reasoned, then EPA approval of a pesticide must too. That equation, a government agency’s approval treated as a binding legal requirement, is the real engine of the decision, and it is why the ruling could reach well beyond Roundup.
Complete a Free Case Evaluation form now
Justice Ketanji Brown Jackson, joined by Justice Neil Gorsuch, dissented, and her reasoning is, in our view, the better one. Federal law says that registering a pesticide is only evidence that its label follows the rules, not final proof; in fact, a pesticide can be properly registered and still be illegally mislabeled. If the EPA’s approval is not the last word, Jackson argued, it cannot be the kind of binding requirement the majority treated it as. The real rule is the law’s ongoing ban on misleading or inadequate labels, and a state lawsuit demanding an honest warning simply enforces that same rule rather than adding a new one. As she put it, the majority’s reading “unjustifiably closes the courthouse doors to state tort plaintiffs like Durnell.” She also pointed out that the EPA has, on at least six occasions, allowed companies to add cancer warnings on their own, one of them a Bayer subsidiary, which undercuts the claim that Monsanto’s hands were tied.
Call or text (888) 585-2188 or complete a Free Case Evaluation form
Two side notes are worth keeping in mind. The usual ideological lines blurred: Justices Sotomayor and Kagan joined the majority, while Justice Gorsuch joined the dissent. And Justice Thomas, though he sided with the majority, wrote separately to question whether a federal agency should be able to override state law at all, a view that, oddly, would cut against the very result the Court reached.
We are not alone in our concern. The American Association for Justice, the country’s largest organization of trial lawyers, together with Public Justice, filed a friend-of-the-court brief urging the Court to let these lawsuits proceed. After the ruling, the association’s CEO, Linda Lipsen, warned that the decision “tramples every state’s right to protect its own citizens,” shielding the makers of more than 57,000 pesticide products found in homes, schools, and workplaces. The association has called on Congress to step in and restore the rights this decision takes away.
What This Means If You Have Been Hurt by a Drug or Medical Device
It is tempting to assume this ruling now protects every company whose product received a government green light. It does not, and the differences matter a great deal.
The most important point is also the simplest. This decision was about a particular kind of federal law, one that contains an explicit clause overriding state rules. The law governing prescription drugs has no such clause. So whatever the Roundup ruling says about pesticides, it does not automatically apply to the medicines in your cabinet.
Start with medical devices, where the ruling changes little, because it borrowed its logic from device law in the first place. For years, lawsuits over the highest-risk devices, the ones that go through the FDA’s most rigorous “premarket approval,” have largely been blocked. Durnell reinforces that, and hands defense lawyers new ammunition to chip away at the narrow exceptions that have kept some device cases alive. Devices that reach the market through the FDA’s lighter review process are treated differently and remain fair game, and companies will surely test that line.
Brand-name prescription drugs are where fear will run highest and is least justified, if we hold the line. A landmark decision called Wyeth v. Levine holds that FDA approval of a brand-name drug’s label does not block a failure-to-warn lawsuit. The reason is crucial: a brand-name drug maker can strengthen its own warning right away, without waiting for FDA permission. That is the exact power the Roundup maker lacked, and the entire Durnell ruling rests on that lack of power. Where a company could have made its label safer on its own, the foundation of Durnell simply is not there.
Companies will still argue that warning customers was “impossible” because the FDA controlled the label. But the Supreme Court has set a high bar for that argument, in a case called Merck v. Albrecht. A company has to prove two things: first, that it gave the FDA the full picture of the risk; and second, that the FDA formally refused to allow the stronger warning. Vague letters or the offhand opinions of individual agency staff do not count. That is a demanding test, and most companies cannot meet it. It is exactly the argument the trial lawyers’ brief pressed in this case, on a point the ruling never even reached.
Generic drugs are a different and harder story. Because federal law requires generic makers to copy the brand-name label word for word, courts already block most failure-to-warn claims against them, and nothing here improves that. Over-the-counter drugs are a closer call. The law covering them does contain an override clause, but it also expressly preserves people’s right to sue under state product-liability law, a protection pesticides never had. Defending that protection should be a priority.
Strip away the legal machinery and a single question runs through all of it: could the company have made its label safer on its own? Pesticide makers, the highest-risk device makers, and generic drug makers generally cannot, and their failure-to-warn cases are now blocked or badly weakened. Brand-name drug makers can, which is why the protection for people harmed by those drugs still stands. The effort in the coming years will be to blur that line and turn this ruling into a blanket rule that government approval equals immunity. Our job is to hold companies to what the Court actually said, not what they wish it had said.
The courthouse doors did not slam shut on Thursday. They narrowed, in one corner of one law, on reasoning that courts are not required to stretch any further. If you or someone you love has been harmed by a pesticide, a medication, or a medical device, your path to holding a company accountable may be more complicated than it was a week ago, but it is far from closed. We are continuing to review and take on these cases, and we would welcome the chance to talk through what this decision means for your situation.